FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3020183939> ?p ?o ?g. }

• W3020183939 endingPage "2070" @default.
• W3020183939 startingPage "2050" @default.
• W3020183939 abstract "Patients with myeloproliferative neoplasms (MPNs), a group of rare haematological conditions including polycythaemia vera, essential thrombocythaemia, and myelofibrosis, often experience a range of symptoms which can significantly impact their quality of life (QoL). Although symptom burden is highest in myelofibrosis and high-risk patients, lower-risk patients also report symptoms impacting their daily life and ability to work. In addition to physical symptoms, MPNs affect emotional well-being, with anxiety and depression frequently reported by patients. Despite significant advances in treatment options, such as the introduction of JAK1/JAK2 inhibitors, therapy for MPNs is often palliative; therefore, reduction of symptoms and improvement of QoL should be considered as major treatment goals. One of the main issues impacting MPN treatment is the discord between patient and physician perceptions of symptom burden, treatment goals, and expectations. New technologies, such as app-based reporting, can aid this communication, but are still not widely implemented. Additionally, regional variation further affects the psychosocial burden of MPNs on patients and their associates, as treatments and access to clinical trials are options for patients living in some areas, but not others. Overcoming some of the challenges in patient–physician communication and treatment access are key to improving disease management and QoL, as well as giving the patient greater input in treatment decisions. Myeloproliferative neoplasms (MPNs) are a group of blood diseases where the body makes too many blood cells. Patients with MPNs can have symptoms which interfere with their daily lives, such as tiredness, pain, sweating at night, dizziness, itching, and difficulty sleeping. They also often suffer from anxiety and/or depression. In nearly all cases, physicians cannot cure the disease, but drugs can prevent blood clots and reduce the speed at which the disease gets worse. Usually, the main aim of treatment is improving patients’ quality of life (QoL). Targeted drugs, such as ruxolitinib, treat MPNs and reduce symptoms, but do not cure the disease. Patients frequently want to play a bigger part in decisions about their treatment. However, physicians and patients often have different views on how well treatments are working and what to expect from the treatment. This can mean that patients feel they are not getting the best treatment for their symptoms. Also, patients may not be able to get some treatments or take part in a trial of a new drug, depending on where they live. This creates feelings of unfairness which can affect their mental health. Addressing all these problems may help improve the QoL for patients with these blood diseases." @default.
• W3020183939 created "2020-05-01" @default.
• W3020183939 creator A5014473495 @default.
• W3020183939 creator A5084145438 @default.
• W3020183939 date "2020-04-23" @default.
• W3020183939 modified "2023-10-06" @default.
• W3020183939 title "The Myeloproliferative Neoplasm Landscape: A Patient’s Eye View" @default.
• W3020183939 cites W1534089060 @default.
• W3020183939 cites W1537482037 @default.
• W3020183939 cites W1825604416 @default.
• W3020183939 cites W1966046397 @default.
• W3020183939 cites W1980508097 @default.
• W3020183939 cites W1991495650 @default.
• W3020183939 cites W2030868349 @default.
• W3020183939 cites W2043993681 @default.
• W3020183939 cites W2090885521 @default.
• W3020183939 cites W2098215007 @default.
• W3020183939 cites W2115351357 @default.
• W3020183939 cites W2116878961 @default.
• W3020183939 cites W2121743767 @default.
• W3020183939 cites W2122395736 @default.
• W3020183939 cites W2129475142 @default.
• W3020183939 cites W2138709799 @default.
• W3020183939 cites W2144664431 @default.
• W3020183939 cites W2161021913 @default.
• W3020183939 cites W2173715636 @default.
• W3020183939 cites W2177135392 @default.
• W3020183939 cites W2287857102 @default.
• W3020183939 cites W2473936309 @default.
• W3020183939 cites W2513623177 @default.
• W3020183939 cites W2523098143 @default.
• W3020183939 cites W2529479111 @default.
• W3020183939 cites W2566135695 @default.
• W3020183939 cites W2587685665 @default.
• W3020183939 cites W2604202516 @default.
• W3020183939 cites W2606410677 @default.
• W3020183939 cites W2612868058 @default.
• W3020183939 cites W2617895748 @default.
• W3020183939 cites W2622547803 @default.
• W3020183939 cites W2742790272 @default.
• W3020183939 cites W2744846745 @default.
• W3020183939 cites W2754551124 @default.
• W3020183939 cites W2759277150 @default.
• W3020183939 cites W2760125330 @default.
• W3020183939 cites W2769707416 @default.
• W3020183939 cites W2775863185 @default.
• W3020183939 cites W2778275419 @default.
• W3020183939 cites W2784807777 @default.
• W3020183939 cites W2790003237 @default.
• W3020183939 cites W2791240656 @default.
• W3020183939 cites W2793337215 @default.
• W3020183939 cites W2795241918 @default.
• W3020183939 cites W2801656776 @default.
• W3020183939 cites W2803273381 @default.
• W3020183939 cites W2803381821 @default.
• W3020183939 cites W2805613569 @default.
• W3020183939 cites W2808491541 @default.
• W3020183939 cites W2809900072 @default.
• W3020183939 cites W2889471460 @default.
• W3020183939 cites W2896385413 @default.
• W3020183939 cites W2903319422 @default.
• W3020183939 cites W2904157469 @default.
• W3020183939 cites W2904349415 @default.
• W3020183939 cites W2912193416 @default.
• W3020183939 cites W2975603087 @default.
• W3020183939 cites W4210297421 @default.
• W3020183939 cites W4246545933 @default.
• W3020183939 cites W4249369999 @default.
• W3020183939 cites W4251944893 @default.
• W3020183939 doi "https://doi.org/10.1007/s12325-020-01314-0" @default.
• W3020183939 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7467498" @default.
• W3020183939 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32329011" @default.
• W3020183939 hasPublicationYear "2020" @default.
• W3020183939 type Work @default.
• W3020183939 sameAs 3020183939 @default.
• W3020183939 citedByCount "12" @default.
• W3020183939 countsByYear W30201839392021 @default.
• W3020183939 countsByYear W30201839392022 @default.
• W3020183939 countsByYear W30201839392023 @default.
• W3020183939 crossrefType "journal-article" @default.
• W3020183939 hasAuthorship W3020183939A5014473495 @default.
• W3020183939 hasAuthorship W3020183939A5084145438 @default.
• W3020183939 hasBestOaLocation W30201839391 @default.
• W3020183939 hasConcept C118552586 @default.
• W3020183939 hasConcept C126322002 @default.
• W3020183939 hasConcept C139719470 @default.
• W3020183939 hasConcept C150966472 @default.
• W3020183939 hasConcept C159110408 @default.
• W3020183939 hasConcept C162324750 @default.
• W3020183939 hasConcept C177713679 @default.
• W3020183939 hasConcept C1862650 @default.
• W3020183939 hasConcept C2776867660 @default.
• W3020183939 hasConcept C2778740236 @default.
• W3020183939 hasConcept C2779134260 @default.
• W3020183939 hasConcept C2779951463 @default.
• W3020183939 hasConcept C2780007613 @default.
• W3020183939 hasConcept C2780076729 @default.
• W3020183939 hasConcept C2781107747 @default.

• next